PHAT Stock Summary and Trading Ideas (Phathom Pharmaceuticals | NASDAQ:PHAT)

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Phathom Pharmaceuticals trades on the NASDAQ stock market under the symbol PHAT.

As of March 30, 2026, PHAT stock price declined to $10.53 with 1,215,006 million shares trading.

PHAT has a beta of 2.05, meaning it tends to be more sensitive to market movements. PHAT has a correlation of 0.10 to the broad based SPY ETF.

PHAT has a market cap of $821.48 million. This is considered a Small Cap stock.

Last quarter Phathom Pharmaceuticals reported $58 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $149,900 and exceeded earnings estimates by $.11.

In the last 3 years, PHAT traded as high as $19.71 and as low as $2.21.

The top ETF exchange traded funds that PHAT belongs to (by Net Assets): VTI, IWM, VXF, XPH, IBB.

PHAT has outperformed the market in the last year with a price return of +57.4% while the SPY ETF gained +12.7%. However, in the short term, PHAT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -40.0% vs -8.2% return in SPY. But in the last 2 weeks, PHAT shares have fared better than the market returning +1.5% compared to SPY -4.3%.

PHAT support price is $10.06 and resistance is $11.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHAT shares will trade within this expected range on the day.